2020 Annual Report - Boston Scientific

1 2020 Annual ReportBOSTON Scientific 2020 Annual REPORTB oston Scientific Corporation300 Boston Scientific WayMarlborough, MA 2021 Boston Scientific Corporation or its affiliates. All rights 13/15/21 1:02 PM3/15/21 1:02 PMStock ListingBoston Scientific Corporation common stock is traded on the NYSE under the symbol BSX. Transfer Agent Inquiries concerning the transfer or exchange of shares, lost stock certificates,duplicate mailings, or changes of address should be directed to the Company s Transfer Agent at:Computershare Box 30170 College Station, TX 77842-3170 Shareholder website: online inquiries: Registered Public Accounting Firm Ernst & Young LLP Boston , Massachusetts Annual Meeting The 2021 Annual meeting of stockholders will take place on Thursday, May 6, 2021, beginning at 8:00 Eastern Time. The Annual meeting will be held in a virtual format only and can be accessed at Other Information Copies of the Company s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports are available free of charge on our website at Corporate Governance Guidelines and our Code of Conduct which applies to all our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer are also available on our website.

2 Certifications of the Chief Executive Officer and Chief Financial Officer certifying the accuracy of the Company s public disclosures have been filed with the Securities and Exchange Commission as exhibits to the Company s Annual Report on Form 10-K for the year ended December 31, of these reports are also available by directing requests to:Investor Relations Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 508-683-4000 508-647-2200 (Facsimile) Information Requests Investors, stockholders and security analysts seeking information about Boston Scientific should refer to our website at or contact Investor Relations at 508-683-4000, or by email at Headquarters Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 508-683-4000 Investor Relations Facsimile: 508-647-2200 Information on or connected to our website (or the website of any third party) referenced in this Annual Report is in addition to and not a part of or incorporated by reference into this Annual Report .

3 Such additional information speaks as of the date thereof and is not intended to be confirmed or updated by reference to it herein. Boston Scientific disclaims any liability or responsibility for or endorsement of the information on or connected to the website of a third of DirectorsNelda J. Connors2,4 Founder and Chief Executive Officer, Pine Grove Holdings, LLCC harles J. Dockendorff 1,4 Former Executive Vice President and Chief Financial Officer, Covidien plcYoshiaki Fujimori 4 Senior Executive Advisor of Japan, CVC Capital PartnersDonna A. James 2,3 Founder, President and Managing Director, Lardon & Associates, LLCE dward J. Ludwig 2 Former Chief Executive Officer and Chairman, Becton, Dickinson and CompanyStephen P. MacMillan2,3 Chairman, President and Chief Executive Officer, Hologic, F. Mahoney Chairman of the Board;President and Chief Executive OfficerDavid J. Roux 1,3Co-Founder, Co-Managing Partner, BayPine CapitalJohn E.

4 Sununu 1,4 Former SenatorEllen M. Zane 1,3 CEO Emeritus, Tufts Medical Center and Tufts Children's HospitalInformation is accurate as of March 1, Member of the Audit Committee2 Member of the Executive Compensation and Human Resources Committee3 Member of the Nominating and Governance Committee4 Member of the Risk CommitteeExecutive OfficersDaniel J. BrennanExecutive Vice President and Chief Financial OfficerArthur C. ButcherExecutive Vice President and President, Asia PacificWendy CarruthersSenior Vice President,Human ResourcesJodi Euerle EddySenior Vice President and Chief Information and Digital OfficerJoseph M. FitzgeraldExecutive Vice President and President, Interventional CardiologyEdward F. MackeyExecutive Vice President,OperationsMichael F. MahoneyChairman of the Board;President and Chief Executive OfficerProfessor Ian T. Meredith, AMExecutive Vice President andGlobal Chief Medical OfficerJeffrey B.

5 MirvissExecutive Vice President and President, Peripheral InterventionsMaulik NanavatySenior Vice President and President, NeuromodulationScott OlsonSenior Vice President and President, Rhythm ManagementDavid A. PierceExecutive Vice President and President, MedSurg;and President, EndoscopyDesiree Ralls-MorrisonSenior Vice President,General Counsel and Corporate SecretaryMeghan ScanlonSenior Vice President and President, Urology and Pelvic Health John B. SorensonSenior Vice President,Manufacturing and Supply ChainEric Th pautExecutive Vice President and President, Europe, Middle East and AfricaStockholder 23/15/21 3:17 PM3/15/21 3:17 PMThroughout 2020, our teams worked nimbly and quickly to support customers, manage costs and put strategies in place to navigate through uncertainty. We enhanced our digital capabilities to serve customers in new ways, launched innovative products and touched the lives of close to 30 million patients.

6 We contributed more than $18 million in aid to global COVID-19 relief efforts, through monetary and supply donations and by volunteering and providing engineering and manufacturing expertise and resources. We also strengthened our commitment to diversity, equity and inclusion and took action to confront racism and advance social unmet needs in healthcare are great, and we have much work to do, but I m proud of our successes and know they have been possible because of the incredible winning spirit of our 38,000 employees and the values that define and guide our company. As a result of the agility and resilience our teams have shown, our business remains strong, and we believe we are well-positioned to return to consistent growth when the pandemic subsides and medical procedure volumes Business ResultsThe decline and deferral of elective procedures due to the pandemic affected our revenue and earnings.

7 As a result, our 2020 financials are an exception to what has been a nearly six-year trend of excellent performance. Our full-year net sales in 2020 were $ billion. This represents declines of percent on an operational1 basis and percent on an organic2 basis compared to 2019, both of which include a 170-basis point impact associated with the conversion of WATCHMAN customers to a consignment inventory model and transition to the next-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. Organic2 revenue declined by percent in MedSurg , by percent in Rhythm and Neuro, and by percent in Outside of our three reporting segments, our Specialty Pharmaceuticals4 business generated revenue of $219 million. Our worldwide performance reflected the effects of COVID-19, with declines in operational1 revenue of percent in the United States, percent in EMEA, percent in APAC, and percent in Latin America and Canada compared to 2019.

8 Annual sales in Emerging Markets5 countries were also affected, declining percent on an operational1 adjusted operating margin6 for the full year was percent, with adjusted earnings per share6 of $ , compared to $ a year ago. This reflects the impact of reduced procedure volumes due to COVID-19 as well as the discontinuation of the LOTUS Edge Aortic Valve System and impact from the shift to the consignment model for the WATCHMAN franchise. Despite these challenges, we generated $2 billion in adjusted free cash flow,7 with free cash flow8 of $ billion. With our innovative pipeline, strong commercial presence and ongoing expansion into higher growth markets, we continue to execute against our strategic plan objectives and drive towards ex-COVID-199 financial goals for 6-8% organic2 sales growth, expanded adjusted operating margins6 and double-digit adjusted earnings per share6 growth.

9 We believe this momentum, combined with our ability to generate and deploy strong free cash flow, positions Boston Scientific well to create future shareholder value. Positioned for GrowthBoston Scientific products are used to help diagnose or treat complex diseases and conditions across multiple fields: cardio-vascular, respiratory, digestive, neurological, urological and pelvic health. By deepening our portfolio in these areas, our category leadership strategy creates value for patients, physicians and payors. We believe our strong balance sheet and businesses will enable us to continue to pursue growth and expand our presence in new markets and regions and make our technologies accessible to more people in need. As of December 31, 2020, we had $ billion in cash on hand, which will enable us to continue to make strategic, growth-enhancing Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 6 and 7.

10 2 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and net sales from recent acquisitions and divestitures with less than a full year of comparable net sales. See non-GAAP reconciliations on pages 6 and 7. 3 We have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices). We have included the results of BTG s Interventional Medicine business in our Peripheral Interventions operating segment since the date of acquisition. 4 As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals), a stand-alone operating segment presented alongside our Medical Device reportable segments. On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business to Stark International Lux and SERB SAS, affiliates of SERB, for a purchase price of $800 million.